The Procurement Lens.
Category intelligence · R&D · Clinical research (CRO)

Clinical research (CRO)

Full-service and functional (FSP) clinical trial outsourcing, preclinical safety testing, central labs, site and patient services.

Strategic · large, complex spend where delay costs far more than price

At a glance

CRO demand, Q3 2026

IQVIA R&D bookings
$3.2bn
+15% YoY; book-to-bill 1.2x
OfficialIQVIA Q3 2026 results (8-K) · 27 Oct 2026
ICON net book-to-bill
1.56x
Record $3.15bn net wins
OfficialICON plc · 27 Oct 2026
Medpace awards
+10.6%
$873m, a quarterly record
OfficialMedpace Q3 2026 results (8-K) · 21 Oct 2026
ICON revenue
-2.9%
Bookings not yet in revenue
OfficialICON plc · 27 Oct 2026
CRO demand has turned: IQVIA, ICON, Medpace and Charles River all reported book-to-bill above 1x in Q3 2026. That shifts leverage toward suppliers for 2027 awards. Lock rates, change-order rules and pass-through controls now, while CROs still want to convert bookings into revenue.

Exhibit 1CRO book-to-bill, Q3 2026

New net awards divided by revenue; above 1.0 means backlog is growing

ICON1.56xMedpace1.22xIQVIA (R&D)1.2xCharles River (preclinical)1.09xBreak-even1x
Showing: Global

The category on a page

What it isOutsourced clinical trials (Phase I-IV), preclinical safety testing, central labs, site and patient recruitment.
How bigIQVIA alone holds a $32.6bn contracted R&D backlog; ICON $24.5bn.
Market structureLarge full-service CROs (IQVIA, ICON, Parexel, Thermo Fisher PPD), mid-size specialists (Medpace), preclinical (Charles River), regional players.
PositioningStrategic: high cost, high impact on time to market, few qualified suppliers per trial.
Key riskChange orders, pass-through overruns and slow patient enrolment.
Primary leverScope control, unit pricing, pass-through governance and performance credits.

Exhibit 2Where clinical research sits

Profit impact against supply risk, R&D subcategories

ROUTINELEVERAGEBOTTLENECKSTRATEGICClinical researchContract manufacturingAPIsLab suppliesProfit impact →Supply risk →
JudgementThe Procurement Lens assessment

Exhibit 3Q3 2026 revenue growth

Year on year

IQVIA R&D Solutions+8.7%Medpace+8.5%Charles River (organic)+4.7%ICON-2.9%
OfficialIQVIA Q3 2026 results (8-K) · Oct-Nov 2026

Exhibit 4Contracted backlog

$bn, 30 Sep 2026

IQVIA (R&D)$32.6bnICON$24.5bnMedpace$3.2bnCharles River (DSA)$2bn
OfficialCompany Q3 2026 results · Oct-Nov 2026

Typical savings vs unmanaged award

Base contract plus change orders and pass-throughs

5%12%
0%10%20%
JudgementThe Procurement Lens judgement: change orders and pass-throughs are where most overruns sit

Value levers

In order of value.

01Lock scope and govern change orders

Fixed assumptions, a change-order rate card and a cap on unapproved changes.

CRO margin is made on changes
JudgementThe Procurement Lens
02Control pass-throughs and site grants

Benchmark investigator grants; pay pass-throughs at cost with receipts.

ICON raised 2026 guidance partly on higher pass-through activity
03Choose FSP or full service by study

FSP for resource control; full service for turnkey studies.

IQVIA cites strength in full service bookings
04Unit-based pricing

Price per patient, site and visit instead of FTE hours.

Hides less utilisation risk
JudgementThe Procurement Lens
05Performance credits on enrolment

Credits for missed enrolment, data and database-lock dates.

Delay costs more than any rate saving
JudgementThe Procurement Lens
06Use AI productivity in price

Ask for AI-driven efficiency to show in monitoring and data-management units.

IQVIA has 400+ AI agents in use

How to buy it

Sourcing routePreferred-provider panel of 2-3 full-service CROs plus FSP partners; study-level mini-bids.
Pricing modelUnit-based budget with fixed management fee; pass-throughs at cost; change-order rate card.
Contract termsEnrolment and quality KPIs with credits, data ownership and exit, audit rights, AI and data-use terms.

KPIs to track

For the monthly review

Change orders as % of basePass-through varianceEnrolment vs planTime to database lockCost per patient

Where most buyers are, and what good looks like

Most buyers todayBest practice
ModelStudy-by-study award→Panel with FSP and full-service mix
PricingFTE hours→Unit-based with benchmarks
ChangesApproved after the fact→Rate card and pre-approval
Pass-throughsInvoice as billed→At cost, reconciled monthly
PerformanceReports only→KPIs with credits

What AI changes

More in the AI disruption tab.

AI site selection and recruitment cut timelines.
AI data cleaning reduces monitoring hours.
CROs may price 'AI-enabled' as a premium.

From the category playbook

Clinical research (CRO)

PositioningPivotal full-service trials & strategic partnerships - Strategic · FSP & niche labs - Leverage
Recommended routeStrategic CRO partnership(s) for core programmes; FSP for scalable functions; competitive bids per study
Spec approachUnit-based/outcome pricing; tight change-order governance; transparent pass-through & investigator grants; quality/timeline KPIs
Top value levers1) Operating model (FSP vs full-service) 2) Change-order & pass-through control 3) Dual-sourcing & low-cost-region trial placement
Key riskTrial-cost inflation · timeline/quality risk · recruitment · change-order leakage
Headline KPIsCost per patient/site · change-orders vs baseline · enrolment rate · data quality/query rate · timeline adherence
What it isOutsourced drug development - preclinical, clinical-trial management (Phase I-IV), data management, biostatistics, labs and regulatory.
Spend profileMonitoring/site & investigator costs and FTE/day-rates drive cost. CRO market ~$91-95B, ~9-10% growth (2026).
Market structureA few global CROs (IQVIA, ICON, Fortrea, Parexel, Thermo Fisher/PPD, Medpace) + regional/APAC specialists; NA ~50% of spend.
Kraljic leanFull-service pivotal trials & strategic partnerships = Strategic; FSP & niche labs = Leverage.
Key riskTrial complexity & cost inflation; timeline/quality risk; patient recruitment; change-order leakage; lock-in.
Primary leverFSP vs full-service model choice + unit/outcome pricing + change-order control + dual-sourcing & regional trial placement.

Exhibit 5Kraljic positioning (category playbook)

Sub-categories by profit impact and supply risk

ROUTINELEVERAGEBOTTLENECKSTRATEGICFull-service pivotal trialsFSP (functional)Lab / bioanalyticalData mgmt / biostatsProfit impact →Supply risk →
JudgementThe Procurement Lens category tool

Exhibit 6Where the money goes

Typical cost split

35%28%20%17%
Monitoring / CRA effortInvestigator / site grantsLab & data managementProject mgmt / other
JudgementThe Procurement Lens category tool

Exhibit 7CRO market growth to 2031 by segment

CAGR %

Clinical-trial mgmt+8.1%Overall CRO+7.8%Early phase+6.4%Biotech CRO+5.7%
OfficialCategory tool benchmark

Savings potential (category playbook)

Typical range on addressable spend

8%18%
0%20%40%
T4Category tool estimate

Verified benchmarks - Global

  • Global CRO market ~$87-99B in 2026, growing ~7.8%/yr to 2031; clinical-trial management is the fastest segment (~8.1% CAGR)
  • IQVIA backlog ~$34B on a 1.22× book-to-bill; emerging-biopharma funding ~$35B in Q2 (2× YoY) with double-digit RFP growth - demand improving but uneven
  • North America ~50% of spend; Asia-Pacific fastest-growing on cost and patient pools - no public price index, priced per unit / FSP / full-service
T1 Official statisticsT2 Industry index / surveyT3 Analyst / consultingT4 AI estimate

Supplier landscape - Global

Top global players and the local or regional players that matter here. Illustrative, from public sources; not an endorsement.

Global players

Global CROs

Value levers (category playbook)

CRO is a scope-and-pass-through game - the headline unit rate is a fraction of the story; the money is in change-order discipline, pass-through and investigator-grant control, and the functional-vs-full-service model, not the FTE rate.

1Change-order discipline

Lock scope and govern change orders hard - CRO margin is made on changes, and unmanaged change orders routinely exceed the base award.

Change orders can rival the base contract
2Pass-through & grant control

Benchmark and control pass-throughs and investigator/site grants separately; these are large, opaque and often un-negotiated.

Pass-throughs a major, controllable cost
3FSP vs full-service model

Decide functional-service-provider vs full-service by trial type; FSP gives rate and resource control, full-service gives convenience at a premium.

FSP for control; full-service for turnkey
4Unit-based pricing & benchmarks

Move to transparent unit/activity-based pricing (per patient, per site, per monitoring visit) with benchmarks; FTE-based pricing hides utilisation.

Unit pricing > FTE where feasible
5Performance KPIs with credits

Contract enrolment, data-quality and timeline KPIs with credits; CRO underperformance delays the trial, which dwarfs any sourcing saving.

KPI credits on enrolment/quality/timeline

Make AI do the work

AI and decentralised-trial tech are changing CRO economics - AI in site selection, patient recruitment and data cleaning cuts cost and timelines. Demand that providers deploy it and share the saving, and watch for 'AI-enabled' premium pricing on what's becoming table stakes. In a category where speed-to-data is the real value, the AI question is timeline compression, not just rate.

Reactive vs proactive (category playbook)

ReactiveProactive
ModelFull-service fixed bid→Unit-based + FSP mix; cap change orders
ScopeAccept change orders→Tight scope + change-order governance
SourcingSingle preferred CRO→Dual-CRO / FSP for leverage & continuity
SitesCRO-selected sites→Data-driven site & country selection
OversightTrust CRO reporting→Risk-based monitoring + your own KRIs

How AI is changing the category

  • AI accelerates patient recruitment, site selection and protocol design - cutting timelines and cost.
  • Risk-based monitoring + AI reduces costly on-site CRA effort.
  • AI data management/query automation and synthetic control arms lower study cost.
  • AI estimation tools expose padded bids and change-order patterns.

What to do about it

  • Reward CROs that use AI recruitment/RBM with timeline- and cost-linked terms.
  • Benchmark bids and change-orders with AI; insist on unit/outcome pricing.
  • Explore AI/synthetic-control and decentralised-trial designs to cut patient cost.
  • Place trials in cost-effective regions and dual-source to keep leverage.

Each number carries source, as-of date and a credibility tier (T1 official · T2 index/survey · T3 analyst · T4 estimate). Figures are market-size/growth forecasts (Mordor/Fortune) and IQVIA bookings data - no public price index exists, so studies are priced per unit/protocol (FSP/full-service). Demand is improving but uneven; control change-orders and pass-throughs, reward AI-enabled recruitment/RBM, and place trials by cost and patient access.

Full written analysis

Written live for Clinical research (CRO) and your region, grounded on the figures above. Public data only.

Written live for this category and region when the page opens in a browser.

Sources

Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.